^
Association details:
| Biomarker: | MSI-H/dMMR + KRAS Mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
Published date:
07/04/2021
Excerpt:
For the 119 treated patients...25% had BRAF mutation, 37% had KRAS mutation. ORR benefit was observed across evaluated subgroups by BRAF/KRAS mutation status...Nivolumab plus low-dose ipilimumab provided durable clinical benefit (ORR, PFS, and OS) over 13.4, 25.4, and 50.9 months of follow-up. Extended follow-up showed increasing ORR and deepening of response. These results demonstrate long-term benefit of nivolumab plus low-dose ipilimumab for previously treated patients with MSI-H/dMMR mCRC.
DOI:
https://doi.org/10.1016/j.annonc.2021.05.051
Trial ID:
Source:
Title:
Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy: Two-year clinical update.
Published date:
01/11/2021
Excerpt:
ORR was similar in pt subgroups by BRAF/KRAS mutation status...NIVO + low-dose IPI demonstrated robust, durable clinical benefit; was well tolerated with 2-year follow-up; and was consistent in evaluated subgroups in 1L MSI-H/dMMR mCRC.
Trial ID:
